New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

Rights & Permissions

Free PDF Access

Free Resources

Related Titles

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

Page
109


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Herpes simplex viruses 1 & 2	Glycoprotein produced by recombinant DNA technology	Children up to age 12 and older susceptibles	3,788,337	4	15	10	25	378,833,700	379
	Attenuated live virus		3,788,337	1	15	10	25	94,708,425	95
Herpesvirus varicellae	Attenuated live virus	Recipients of bone marrow and organ transplants and persons under age 25 with leukemias or lymphoms	12,757	2	25	10	35	892,990	0.9
		Normal susceptibles, routine for children (booster for adults)	3,788,337	2	18.75	10	28.75	217,829,378	218
Influenza viruses A & B	Subunit vaccine (purified hemagglutinin/neuraminidase proteins)	High-risk population as currently defined (see Appendix K)	48,000,00	a	a	a		200,160,000	200
	Attenuated live virus	High-risk population as currently defined	48,00,000	a	a	a		197,760,000	198
Neisseria gonorrhoeae	A small number of promising options need investigation to determine best approach	Adolescents and adults age 15 and over	3,669,254	3	20	10	30	330,232,860	330
Parainfluenza viruses	Trivalent, subunit vaccine (must contain fusion protein)	Infants	3,788,337	2	11.25	10	21.25	161,004,323	161
Respiratory syncytial virus	Glycoprotein produced by recombinant DNA technology	Infants	3,788,337	2	11.25	10	21.25	161,004,323	161
	Attenuated live virus	Infants	3,788,337	1	11.25	10	21.25	80,502,161	81
Rotavirus	Attenuated live bovine virus	Infants	3,788,337	1.5	7.5	10	17.5	99,443,846	99
	Attenuated live human or reassortment virus	Infants	3,788,337	1.5	7.5	10	17.5	99,443,846	99
Streptococcus group B	Conjugated polysaccharide	Pregnant women for fetuses and neonates	31788,337	1	22.5	10	32.5	123,120,953	123
^aSee text for explanation of the assumptions underlying these calcuations. Costs are upper limits; they are not adjusted for anticipated utilization.